共 50 条
- [21] EUROPEAN PATENT PRACTICE IN THE PHARMACEUTICAL FIELD .2.IIC-INTERNATIONAL REVIEW OF INDUSTRIAL PROPERTY AND COPYRIGHT LAW, 1983, 14 (03): : 372 - 388MICHAELIS, TV
- [22] Markups and Fixed Costs in Generic and Off-Patent Pharmaceutical MarketsREVIEW OF ECONOMICS AND STATISTICS, 2023, 105 (06) : 1606 - 1614Ganapati, SharatMckibbin, Rebecca
- [23] THE EFFECT OF GENERIC SUBSTITUTION LAWS ON GENERIC DRUG USE: A CASE-STUDY OF THE PATENT EXPIRATION OF ZOCORJOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 : 182 - 183Shrank, W.Choudhry, N. K.Agnew-Blais, J.Federman, A.Liberman, J. N.Kesselheim, A.Brookhart, M. A.Fischer, M.
- [24] The Eleventh Circuit holds that agreements in which pharmaceutical companies pay generic companies not to compete may be validJOURNAL OF LAW MEDICINE & ETHICS, 2004, 32 (01): : 181 - 184Garrigues, A
- [25] GENERIC ENTRY BEFORE THE AGREED-UPON DATE IN PHARMACEUTICAL PATENT SETTLEMENTSJOURNAL OF COMPETITION LAW & ECONOMICS, 2020, 16 (02) : 188 - 219Drake, Keith M.McGuire, Thomas G.
- [26] Managing the challenges of pharmaceutical patent expiry: a case study of LipitorJOURNAL OF SCIENCE AND TECHNOLOGY POLICY MANAGEMENT, 2016, 7 (03) : 258 - 272Chao, Chon KitHu, HaoZhang, LimingWu, Jihong
- [27] ASSESING THE IMPACT OF PATENT LOSS ON OVERALL REVENUES AND STOCKS PRICE OF PHARMACEUTICAL COMPANIESVALUE IN HEALTH, 2014, 17 (07) : A785 - A785Furnback, W.Wang, B. C. M.
- [28] Long way down - pharmaceutical companies fear falling off 'patent cliff'inPHARMACEUTICAL PATENT ANALYST, 2012, 1 (03) : 240 - 240Sklan, Alexandra
- [30] PHARMACEUTICAL COMPANIES PRICING STRATEGIES AFTER GENERIC ENTRY INTO THE NEW ZEALAND MARKETVALUE IN HEALTH, 2014, 17 (03) : A13 - A14Rodriguez-Monguio, R.Seoane-Vazquez, E.